Replimune (REPL) – Press Releases
-
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Asso
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
-
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
-
Replimune to Present at Three Upcoming Investor Conferences
-
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
-
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
-
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed M
-
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
-
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
-
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at
-
Tessellate BIO Emerges from Stealth
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
-
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
-
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
-
Replimune to Present at Two Upcoming Investor Conferences
-
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
-
Replimune Announces Sander Slootweg will Depart from its Board of Directors
-
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
-
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
-
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Replimune to Present at the Jefferies Global Healthcare Conference
-
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
-
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
-
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
-
Replimune to Present at Two Upcoming Investor Conferences
-
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
-
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
-
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Replimune Announces Pricing of Public Offering
-
Replimune Announces Proposed Public Offering
-
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
-
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
-
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
-
Replimune to Host Virtual Investor Event on December 7, 2022
-
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
-
Replimune to Present at Two Upcoming Investor Conferences
-
Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
-
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
-
Replimune to Present at Two Upcoming Investor Conferences
-
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
-
Replimune to Present at the Jefferies Healthcare Conference
-
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
-
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
Back to REPL Stock Lookup
